We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Location: United States, Massachusetts, Watertown
Total raised: $59.5M
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.02.2020 | Series C | $30M | - |
| 26.09.2018 | - | $29.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 03.06.2025 | Wall Street's Balancing Act: Navigating Tariffs and Tech Triumphs | Wall Street is a tightrope walker, balancing between the weight of tariffs and the buoyancy of tech innovation. Recent events have stirred the pot, creating a cocktail of uncertainty and opportunity. The market's pulse quickens as oil price... |
| 02.06.2025 | Wall Street drifts closer to records as oil prices jump and US manufacturing slumps | The past weekend’s attacks by Ukraine in Russia, meanwhile, helped to raise uncertainty about the flow of oil and gas around the world. Monday’s market moves also came after more harsh rhetoric crossed between the world’s two largest econom... |
| 03.02.2020 | Daily funding roundup - February 3th, 2020 | Baton Systems raised $4M; LoanStreet landed $5M; Doubtnut secured $15M; Rimilia picks up $15M Scaled Robotics: Scaled Robotics’s industrial robots aim to navigate construction sites and produce 3D maps of them in minutes. Scaled Robotics ha... |
| 03.02.2020 | Lyra Therapeutics Closes $30M Series C Financing | Lyra Therapeutics, Inc., a Watertown, Mass.-based clinical-stage therapeutics company, completed a $30m Series C financing. The round was led by Perceptive Advisors with participation from Clifton Capital as well as participation by existin... |
| 29.01.2020 | Lyra Therapeutics Completes $30 Million Series C | WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ... |
| 26.09.2018 | Lyra Therapeutics raises $29.5M for chronic rhinosinusitis drug implant | Perceptive Advisors led the financing, while new investors RA Capital management, ArrowMark Partners and Soleus Capital participated, along with existing investors Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partn... |
| 26.09.2018 | Lyra Therapeutics Raises $29.5M in Series B Financing | Lyra Therapeutics, Inc. (fka 480 Biomedical, Inc.), a Watertown, Mass.-based clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, raised $29.5m in Series B equity financ... |
| 26.09.2018 | Lyra Therapeutics Announces $29.5 Million Series B | Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, announced today a $29.5 million Series B equity financing. Proceeds from the financing wi... |
| - | Lyra Therapeutics raises $29.5M for chronic rhinosinusitis drug implant | A drugmaker with a product candidate for a sinus inflammation disease has raised an equity financing round to move it into mid-stage clinical development. Watertown, Massachusetts-based Lyra Therapeutics said Wednesday that it had raised $2... |